A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer

Oncology

Volumn 66, Issue 1, 2004, Pages 38-45

  Montemurro, Filippo ^a   Choa, Gabriella ^a   Faggiuolo, Roberto ^a   Donadio, Michela ^b   Minischetti, Monica ^c   Durando, Antonio ^d   Capaldi, Antonio ^a   Vietti Ramus, Guido ^e   Alabiso, Oscar ^f   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Faculty of Medicine and Surgery School of Nursing   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

^e S GIOVANNI BOSCO HOSPITAL   (Italy)

^f MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Breast neoplasm; Docetaxel; HER2; Neoplasm metastasis; Trastuzumab

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GENE OVEREXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INFECTION; LACRIMATION; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOGENE NEU; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; STOMATITIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UP-REGULATION;

EID: 12144289561     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076333     Document Type: Article

References (29)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human cerbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.
2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
3. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
6. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
7. Merlin JL, Barberi-Heyob M, Bachmann N: In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 2002;13:1743-1748.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
9. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
10. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
11. Pegram MD, Slamon DJ: Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999;26:89-95.
12. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
13. Burris HA 3rd: Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28(1 suppl 3):38-44.
14. Uber KA, Nicholson BP, Thor AD, Merkel DE, Goldstein LJ, Gradishar WJ, Sledge GW: A phase II trial of weekly docetaxel (D) and herceptin (H) as first or second-line treatment in HER2 over-expressing metastatic breast cancer (abstract 1949). Proc Am Soc Clin Oncol 2001;20:50b.
15. Nabholtz JM, Pienowski T, Nothfelt D, Eiermann W, Quan E, Fumoleau P, Patel R, Toppmeyer D, Slamon D: Results of two open label multicentre phase II pilot studies with herceptin in combination with docetaxel and pltinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors over-expressing the HER2-neu protooncogene (abstract 695). Eur J Cancer 2001;37:S190.
16. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M: Weekly intravenous recombinant humanized anti-Her2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer (MBC): A pilot study (abstract 1987). Proc Am Soc Clin Oncol 2001;20:60b.
17. Malik U, Sparano JA, Manalo J, Rajdev L, Hopkins U, Fineberg S: Phase II trial of weekly docetaxel (taxotere) alone or in combination with trastuzumab (herceptin) in patients with metastatic breast cancer (abstract 586). Proc Am Soc Clin Oncol 2000;19:148a.
18. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez MR, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999;17:2341-2354.
19. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
20. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P: A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996;74:650-656.
21. Salminen E, Bergman M, Huhtala S, Ekholm E: Docetaxel: Standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single-center study. J Clin Oncol 1999;17:1127-1131.
22. Montemurro F, Choa G, Faggiuolo R, Sperti E, Capaldi A, Donadio M, Minischetti M, Salomone A, Vietti-Ramus G, Alabiso O, Aglietta M: Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer. A pilot phase II study. Am J Clin Oncol 2003;26:95-97.
23. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
24. Wilson EB: Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-212.
25. Baselga J, Tabernero JM: Weekly docetaxel in breast cancer: Applying clinical data to patient therapy. Oncologist 2001;6(suppl 3):26-29.
26. Esmaeli B, Hortobagyi GN: Canalicular stenosis as the underlying mechanism for epiphora in patients receiving weekly docetaxel. Oncologist 2001;6:551-552.
27. Leyland-Jones B: Dose scheduling - Herceptin. Oncology 2001;61(suppl 2):31-36.
28. Carbonel Castellon X, Castaneta-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Baselga J: Efficacy and safety of 3-weekly herceptin (H) monochemotherapy in women with HER2-positive metastatic breast cancer (MBC): Preliminary data from a phase II trial (abstract 73). Proc Am Soc Clin Oncol 2002;21:19a.
29. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 2000;18:2349-2351.